185 related articles for article (PubMed ID: 36205714)
1. Targeting Extracellular Signal-Regulated Protein Kinase 1/2 (ERK1/2) in Cancer: An Update on Pharmacological Small-Molecule Inhibitors.
Fu L; Chen S; He G; Chen Y; Liu B
J Med Chem; 2022 Oct; 65(20):13561-13573. PubMed ID: 36205714
[TBL] [Abstract][Full Text] [Related]
2. ERK inhibition overcomes acquired resistance to MEK inhibitors.
Hatzivassiliou G; Liu B; O'Brien C; Spoerke JM; Hoeflich KP; Haverty PM; Soriano R; Forrest WF; Heldens S; Chen H; Toy K; Ha C; Zhou W; Song K; Friedman LS; Amler LC; Hampton GM; Moffat J; Belvin M; Lackner MR
Mol Cancer Ther; 2012 May; 11(5):1143-54. PubMed ID: 22402123
[TBL] [Abstract][Full Text] [Related]
3. The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy.
Yu Z; Ye S; Hu G; Lv M; Tu Z; Zhou K; Li Q
Future Med Chem; 2015; 7(3):269-89. PubMed ID: 25826360
[TBL] [Abstract][Full Text] [Related]
4. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
Hatzivassiliou G; Song K; Yen I; Brandhuber BJ; Anderson DJ; Alvarado R; Ludlam MJ; Stokoe D; Gloor SL; Vigers G; Morales T; Aliagas I; Liu B; Sideris S; Hoeflich KP; Jaiswal BS; Seshagiri S; Koeppen H; Belvin M; Friedman LS; Malek S
Nature; 2010 Mar; 464(7287):431-5. PubMed ID: 20130576
[TBL] [Abstract][Full Text] [Related]
5. RAF-MEK-ERK pathway in cancer evolution and treatment.
Ullah R; Yin Q; Snell AH; Wan L
Semin Cancer Biol; 2022 Oct; 85():123-154. PubMed ID: 33992782
[TBL] [Abstract][Full Text] [Related]
6. Targeting ERK1/2 protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Apr; 142():151-168. PubMed ID: 30794926
[TBL] [Abstract][Full Text] [Related]
7. ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway.
Kidger AM; Sipthorp J; Cook SJ
Pharmacol Ther; 2018 Jul; 187():45-60. PubMed ID: 29454854
[TBL] [Abstract][Full Text] [Related]
8. Resistance to MEK inhibitors: should we co-target upstream?
Poulikakos PI; Solit DB
Sci Signal; 2011 Mar; 4(166):pe16. PubMed ID: 21447797
[TBL] [Abstract][Full Text] [Related]
9. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.
Yip-Schneider MT; Klein PJ; Wentz SC; Zeni A; Menze A; Schmidt CM
J Pharmacol Exp Ther; 2009 Jun; 329(3):1063-70. PubMed ID: 19258520
[TBL] [Abstract][Full Text] [Related]
10. The overview of Mitogen-activated extracellular signal-regulated kinase (MEK)-based dual inhibitor in the treatment of cancers.
Wang H; Chi L; Yu F; Dai H; Si X; Gao C; Wang Z; Liu L; Zheng J; Ke Y; Liu H; Zhang Q
Bioorg Med Chem; 2022 Sep; 70():116922. PubMed ID: 35849914
[TBL] [Abstract][Full Text] [Related]
11. Flagellin and lipopolysaccharide stimulate the MEK-ERK signaling pathway in chicken heterophils through differential activation of the small GTPases, Ras and Rap1.
Kogut MH; Genovese KJ; He H
Mol Immunol; 2007 Mar; 44(7):1729-36. PubMed ID: 17045653
[TBL] [Abstract][Full Text] [Related]
12. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy.
Friday BB; Adjei AA
Clin Cancer Res; 2008 Jan; 14(2):342-6. PubMed ID: 18223206
[TBL] [Abstract][Full Text] [Related]
13. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
Roberts PJ; Der CJ
Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
[TBL] [Abstract][Full Text] [Related]
14. Design and biological characterization of a series of dual mechanism ERK1/2 inhibitors with a Triazolopyridinone core.
Lotfaliansaremi S; Cornwell S; Casillas C; Sabio M; Tolias P; Windsor W; Paliwal S
Chem Biol Drug Des; 2023 Apr; 101(4):837-847. PubMed ID: 36434749
[TBL] [Abstract][Full Text] [Related]
15. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.
Steelman LS; Franklin RA; Abrams SL; Chappell W; Kempf CR; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo P; Ruvolo V; Evangelisti C; Martelli AM; McCubrey JA
Leukemia; 2011 Jul; 25(7):1080-94. PubMed ID: 21494257
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy.
Daouti S; Wang H; Li WH; Higgins B; Kolinsky K; Packman K; Specian A; Kong N; Huby N; Wen Y; Xiang Q; Podlaski FJ; He Y; Fotouhi N; Heimbrook D; Niu H
Cancer Res; 2009 Mar; 69(5):1924-32. PubMed ID: 19244124
[TBL] [Abstract][Full Text] [Related]
17. MEK1/2 inhibitors in the treatment of gynecologic malignancies.
Miller CR; Oliver KE; Farley JH
Gynecol Oncol; 2014 Apr; 133(1):128-37. PubMed ID: 24434059
[TBL] [Abstract][Full Text] [Related]
18. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
Poulikakos PI; Zhang C; Bollag G; Shokat KM; Rosen N
Nature; 2010 Mar; 464(7287):427-30. PubMed ID: 20179705
[TBL] [Abstract][Full Text] [Related]
19. Extracellular-signal-regulated kinase/mitogen-activated protein kinase signaling as a target for cancer therapy: an updated review.
Najafi M; Ahmadi A; Mortezaee K
Cell Biol Int; 2019 Nov; 43(11):1206-1222. PubMed ID: 31136035
[TBL] [Abstract][Full Text] [Related]
20. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
